March 17, 2026 – iDEL Therapeutics today announced the closing of a EUR 9 million seed financing, establishing its operations and leadership team. The company is pioneering a pipeline of cancer therapeutics that are delivered directly into the cytosol of tumor cells. iDEL’s new approach is compatible with both large and small molecules and aims to unlock historically undruggable intracellular targets and broaden therapeutic windows across cancer indications. The financing was led by BiomedVC wit

Capital strengthens the advancement of EQ504 through key clinical milestones Anticipated net proceeds, along with existing cash and cash equivalents, expected to extend cash runway into 2029 March 13, 2026 --- Equillium, Inc. (“Equillium” or the “Company”) (Nasdaq: EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today announced that it has entered into a definitive securities purchase agreement with RA Capital Management that will

Investment led by T&J Meyer Family Foundation, joined by Varia Ventures, NW Angel Fund and other non-institutional investors Financing advances Combat’s HIVEC® HEAT FDA registration trial to change standard of care in BCG unresponsive NMIBC Future financings to progress patented hyperthermic technology aimed at improving chemotherapy therapeutic efficacy, tolerability and treatment outcomes for advanced bladder and peritoneal cancers Combat Medical (Combat), a medical device company optimisin

MindImmune today announced a transformative $5 million award from the Alzheimer’s Drug Discovery Foundation (ADDF) to accelerate development of its lead therapeutic candidate, MITI-101 — a first-in-class program designed to target immune pathways driving neuroinflammation and neurodegeneration in Alzheimer’s disease. This significant funding underscores growing scientific momentum around immune-mediated mechanisms in Alzheimer’s and positions MindImmune at the forefront of a new wave of therape

AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company developing novel small molecule therapeutics derived from its boron chemistry platform, today announced that it has entered into a securities purchase agreement for a private placement that is expected to result in gross proceeds of approximately $40 million, before deducting placement agent fees and other expenses. The private placement includes participation from Coastlands Capital, Commodore Capital, Vivo Capita

First company to enable precision in vivo genome engineering, combining both cell-specific delivery and programmable, locus-specific gene insertion, with the potential to achieve physiological, durable gene expression for greater therapeutic impact Launching with $82 million in combined seed and Series A financing led by Third Rock Ventures, with participation from RA Capital Management, Yosemite, Sozo Ventures and select individual investors Founded by Jennifer Doudna, Ph.D., Michael Fischbach,

The funding comes weeks after TL1A blocker duvakitug maintained clinical remission rates above 50% in patients with ulcerative colitis and Crohn’s disease in a Phase 2b trial. Teva has secured $400 million in funding from private equity firm Blackstone Life Sciences to help drive the development of duvakitug, a Sanofi-partnered TL1A blocker being trialed for inflammatory bowel diseases. The deal adds to an emerging trend of private equity firms buying into biopharma. Blackstone will disburse t

Extension financing adds new investors, Janus Henderson Investors and RA Capital, with strong renewed participation from existing investors Proceeds will support further clinical development of lead program PHB-050 in food allergy and other atopic conditions Phase 1 clinical trial for PHB-050 remains on track Poplar Therapeutics, Inc., a clinical-stage immunology company developing a new class of anti-IgE therapy to treat food allergy and other atopic conditions, today announced the closing o

March 03, 2026 -- Persevere Therapeutics, Inc. (“Persevere”), a Delaware-incorporated, clinical-stage oncology biotechnology company, today announced its official launch following a period of stealth operations. The company is emerging with a Phase 1b/2a-ready clinical asset and the first close of its Seed financing. As part of its launch, Persevere has acquired the clinical-stage program and related assets for misetionamide (GP-2250) from Geistlich Pharma AG. Misetionamide is a novel, first-i

Initial $50M Series A investment from founding investor RTW Investments Proceeds will fund clinical development of PRO-203 in systemic sclerosis (SSc) and multiple additional severe autoimmune diseases March 03, 2026 -- Prolium Bioscience, Inc. (Prolium), a clinical stage biotechnology company, today announced its launch with a $50 million Series A Financing to develop PRO-203, a potential best-in-class CD20xCD3 T-cell engager, for severe autoimmune disease. The financing was led by its foundin